Halozyme Therapeutics Overview

  • Year Founded
  • 1998

Year Founded

  • Status
  • Public

  • Employees
  • 423

Employees

  • Stock Symbol
  • HALO

Stock Symbol

  • Investments
  • 4

  • Share Price
  • $91.35
  • (As of Friday Closing)

Halozyme Therapeutics General Information

Description

Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. ENHANZE drug delivery technology was introduced with the proprietary enzyme rHuPH20, to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid SC delivery and reduced treatment burden. The company's operations are based in the United States, with minimal long-lived assets located internationally.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 12390 El Camino Real
  • San Diego, CA 92130
  • United States
+1 (858)
Primary Industry
Biotechnology
Other Industries
Drug Delivery
Stock Exchange
NAS
Vertical(s)
Corporate Office
  • 12390 El Camino Real
  • San Diego, CA 92130
  • United States
+1 (858)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Halozyme Therapeutics Stock Performance

As of 20-Nov-2026, Halozyme Therapeutics’s stock price is $91.35. Its current market cap is $10.4B with 114M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$91.35 $92.99 $61.23 - $134.00 $10.4B 114M 2.26M $4.19

Halozyme Therapeutics Financials Summary

As of 30-Sep-2026, Halozyme Therapeutics has a trailing 12-month revenue of $1.8B.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 14,445,830 8,723,072 6,920,571 5,896,685
Revenue 1,802,448 1,396,611 1,015,324 829,253
EBITDA 805,642 496,401 585,527 378,191
Net Income 485,420 316,889 444,091 281,594
Total Assets 3,473,346 2,525,323 2,063,477 1,733,270
Total Debt 3,250,303 2,142,630 1,505,798 1,499,248
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Halozyme Therapeutics Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Halozyme Therapeutics‘s full profile, request access.

Request a free trial

Halozyme Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies.
Biotechnology
San Diego, CA
423 As of 2026

Cary, NC
 

Palo Alto, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Halozyme Therapeutics Competitors (28)

One of Halozyme Therapeutics’s 28 competitors is Heron Therapeutics, a Formerly VC-backed company based in Cary, NC.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Heron Therapeutics Formerly VC-backed Cary, NC
Immune-Onc Therapeutics Venture Capital-Backed Palo Alto, CA
Ayala Pharmaceuticals Corporation Wilmington, DE
Xenetic Biosciences Corporation Framingham, MA
Mission Therapeutics Venture Capital-Backed Cambridge, United Kingdom
You’re viewing 5 of 28 competitors. Get the full list »

Halozyme Therapeutics Patents

Halozyme Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
CA-246488-S Injection device Active 12-Jun-2025
WO-2026222046-A1 Off-body priming device Pending 16-Apr-2025
WO-2026187389-A1 Combination therapy with antibody-drug conjugates and hyaluronidases Pending 05-Mar-2025
WO-2026165589-A1 Subcutaneous delivery of lipid nanoparticle formulations Pending 03-Feb-2025
WO-2026143138-A1 Prefilled autoinfusion device Pending 23-Dec-2024 A61M5/20
To view Halozyme Therapeutics’s complete patent history, request access »

Halozyme Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Halozyme Therapeutics Acquisitions (4)

Halozyme Therapeutics’s most recent deal was a Merger/Acquisition with Halozyme Surf Bio for . The deal was made on 22-Dec-2025.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Halozyme Surf Bio 22-Dec-2025 Merger/Acquisition Drug Delivery
Elektrofi 18-Nov-2025 Merger/Acquisition Drug Delivery
Antares Pharma 24-May-2022 Merger/Acquisition Drug Delivery
Global Yacht Services 11-Mar-2004 Merger/Acquisition Marine
To view Halozyme Therapeutics’s complete acquisitions history, request access »

Halozyme Therapeutics ESG

Risk Overview

Risk Rating

Updated November, 04, 2026

25.11 | Med Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,592

Rank

Percentile

Pharmaceuticals

Industry

of 852

Rank

Percentile

Biotechnology

Subindustry

of 431

Rank

Percentile

To view Halozyme Therapeutics’s complete esg history, request access »

Halozyme Therapeutics Affiliates

Subsidiaries (2)

Name Industry Location Year Founded
Halozyme Surf Bio Palo Alto, CA 2021
Elektrofi Boston, MA 2016

Halozyme Therapeutics FAQs

  • When was Halozyme Therapeutics founded?

    Halozyme Therapeutics was founded in 1998.

  • Where is Halozyme Therapeutics headquartered?

    Halozyme Therapeutics is headquartered in San Diego, CA.

  • What is the size of Halozyme Therapeutics?

    Halozyme Therapeutics has 423 total employees.

  • What industry is Halozyme Therapeutics in?

    Halozyme Therapeutics’s primary industry is Biotechnology.

  • Is Halozyme Therapeutics a private or public company?

    Halozyme Therapeutics is a Public company.

  • What is Halozyme Therapeutics’s stock symbol?

    The ticker symbol for Halozyme Therapeutics is HALO.

  • What is the current stock price of Halozyme Therapeutics?

    As of 20-Nov-2026 the stock price of Halozyme Therapeutics is $91.35.

  • What is the current market cap of Halozyme Therapeutics?

    The current market capitalization of Halozyme Therapeutics is $10.4B.

  • What is Halozyme Therapeutics’s current revenue?

    The trailing twelve month revenue for Halozyme Therapeutics is $1.8B.

  • Who are Halozyme Therapeutics’s competitors?

    Heron Therapeutics, Immune-Onc Therapeutics, Ayala Pharmaceuticals, Xenetic Biosciences, and Mission Therapeutics are some of the 28 competitors of Halozyme Therapeutics.

  • What is Halozyme Therapeutics’s annual earnings per share (EPS)?

    Halozyme Therapeutics’s EPS for 12 months was $4.19.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process